| Autor: |
Gross G; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Pôle de Psychiatrie et Psychologie Clinique, Centre Psychothérapique de Nancy , Laxou, France.; Faculté de Médecine, Université de Lorraine , France., Maruani J; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique des Hôpitaux de Paris (APHP) , Paris, France.; Université de Paris , Paris, France., Vorspan F; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique des Hôpitaux de Paris (APHP) , Paris, France.; Université de Paris , Paris, France., Benard V; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Université de Lille, CNRS, CHU Lille, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives , Lille, France.; Université de Lille, CHRU Lille, Clinique de Psychiatrie, Unité CURE , Lille, France.; Université de Lille, Hôpital Fontan CHRU , Lille, France., Benizri C; INSERM U955, Equipe Psychiatrie Translationnelle , Créteil, France., Brochard H; Pôle sectoriel, Centre Hospitalier Fondation Vallée , Gentilly, France., Geoffroy PA; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Université de Paris , Paris, France.; Département de psychiatrie et de médecine addictologique, Assistance Publique des Hôpitaux de Paris (APHP), Centre Hospitalo-Universitaire Bichat-Claude Bernard , Paris, France., Kahn JP; Pôle de Psychiatrie et Psychologie Clinique, Centre Psychothérapique de Nancy , Laxou, France.; Faculté de Médecine, Université de Lorraine , France.; Clinique soins-études, Fondation Santé des Etudiants de France , Vitry-le-François, France.; Fondation FondaMental , Créteil, France., Yeim S; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique des Hôpitaux de Paris (APHP) , Paris, France.; Université de Paris , Paris, France., Leboyer M; INSERM U955, Equipe Psychiatrie Translationnelle , Créteil, France.; Fondation FondaMental , Créteil, France.; Faculté de Médecine, Université Paris Est Créteil , Créteil, France.; AP-HP, Hôpitaux Universitaires Henri Mondor, DHU Pepsy, Pôle de Psychiatrie et d'Addictologie , Créteil, France., Bellivier F; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique des Hôpitaux de Paris (APHP) , Paris, France.; Université de Paris , Paris, France.; Fondation FondaMental , Créteil, France., Etain B; INSERM U1144, Optimisation Thérapeutique en Neuropsychopharmacologie , Paris, France.; Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique des Hôpitaux de Paris (APHP) , Paris, France.; Université de Paris , Paris, France.; Fondation FondaMental , Créteil, France. |
| Abstrakt: |
Individuals with bipolar disorder (BD) have higher than average rates of coffee, tobacco and alcohol use. These substances may have deleterious effects on sleep quality and quantity, which may destabilize sleep/wake cycles and negatively impact the clinical course and prognosis of BD. The use of these substances may also be perceived as a self-medication attempt, for example, to induce sleep or to increase vigilance during the day. The objective of the current study was to investigate associations between the self-reported daily use of coffee, tobacco, and alcohol, and objective measures of sleep and activity patterns in adult individuals with BD. A sample of 147 euthymic individuals with BD were assessed for daily coffee, tobacco and alcohol consumption and 21 days of actigraphy monitoring. Actigraphic measures of sleep quantity and daytime activity were compared between groups classified as coffee+/coffee-, tobacco+/tobacco- and alcohol+/alcohol-, defined according to their current daily use. Then, we examined potential correlations between sleep/wake cycle parameters and the amount of daily consumption of each substance. Multivariable analyses identified associations between the use of coffee, tobacco, and alcohol and several sleep and activity parameters, such as between coffee, alcohol, and the relative amplitude of activity (respectively, p = .003 and p = .005), between alcohol and M10 onset (onset time of the 10 most active hours during the 24-h cycle) ( p = .003), and between coffee and sleep duration ( p = .047). This study supports the hypothesis that there is a relationship, whose direction would be bidirectional, between the daily use of these substances and the sleep/wake cycle in euthymic individuals with BD. These preliminary results require replications in other retrospective and prospective samples. They may have a clinical impact on psycho-education strategies to be proposed to individuals with BD. |
